跳转至内容
Merck
CN
  • Prenatal vitamin K1 administration in epileptic women to prevent neonatal hemorrhage: is it effective?

Prenatal vitamin K1 administration in epileptic women to prevent neonatal hemorrhage: is it effective?

The Journal of reproductive medicine (2006-07-19)
Waralak Yamasmit, Surasith Chaithongwongwatthana, Jorge E Tolosa
摘要

To summarize current knowledge on whether prenatal prophylactic vitamin K1 administration to epileptic women receiving enzyme-inducing antiepileptic drugs (AEDs) to prevent neonatal hemorrhage is effective. A computerized MEDLINE search was conducted using the terms antiepileptic drug, hemorrhagic disease of the newborn, pregnancy and vitamin K since 1966 to July 2004, limited only to human studies. English-language publications were selected based on their relevance to the clinical effectiveness of administration of oral vitamin K to epileptic women exposed to enzyme-inducing AEDs for prevention of hemorrhagic disease of the newborn (HDN). No randomized, controlled trial testing prenatal vitamin K1 administration for reducing the incidence or severity of neonatal hemorrhage was identified. This review summarizes the data from published observational studies. There is inadequate evidence to recommend the routine administration of prenatal vitamin K to epileptic women exposed to enzyme-inducing AED therapy in order to prevent HDN.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
维生素 K 1, viscous liquid
Sigma-Aldrich
维生素 K 1, BioXtra, ≥99.0% (sum of isomers, HPLC), mixture of isomers
Supelco
叶绿醌 (K1), analytical standard
Supelco
维生素K1, Pharmaceutical Secondary Standard; Certified Reference Material
维生素 K 1, European Pharmacopoeia (EP) Reference Standard